A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

Johnson & Johnson announces Carvykti demonstrated significantly higher rates of MRD negativity compared to standard therapies in CARTITUDE-4 study: San Diego Wednesday, December 1 ...

"This study provides strong evidence for the use of daratumumab as a treatment for high-risk smoldering multiple myeloma," says Dr. Rajkumar, the Edward W. and Betty Knight Scripps Professor of ...

Treatment with subcutaneous daratumumab significantly improved progression-free survival in patients with intermediate- or high-risk smoldering multiple myeloma.

An expanded analysis from the phase 3 CEPHEUS trial showed that daratumumab plus VRd improved MRD responses as well as ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...

GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

Johnson & Johnson “announced new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI significantly increased ...

GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in ...

GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...